Why is Bavarian Nordic stock in focus today?

Investors are reacting to strong 2025 Travel Health growth of about 30% and a lower 2026 revenue guide of DKK 5.0-5.2bn with an EBITDA margin near 25%. The company also reported DKK 1.3bn of preparedness already contracted, highlighting a softer topline but better visibility as mpox-related demand normalizes.

What does the 2026 guidance imply for profitability?

Management targets an EBITDA margin around 25% in 2026. Mix should help, as Travel Health tends to carry better margins than large public tenders. The margin target suggests cost discipline can offset part of the revenue step-down, but execution on pricing, channel mix, and expenses will be key to meeting that goal.

How does mpox vaccine demand affect results?

Mpox vaccine demand primarily flows through Public Preparedness orders. As outbreaks subside or stockpiling cycles slow, these orders can decline or shift in timing. That is why revenue can be lumpy year to year. The company’s DKK 1.3bn contracted for 2026 offers a base, but incremental tenders will drive upside.

What should US investors track in 2026?

Focus on travel vaccine growth signals, including clinic and pharmacy demand, plus any updates on distribution. Watch for new preparedness tenders, margin commentary against the ~25% target, and currency effects on USD models. Comparing quarterly bookings and mix to the DKK 5.0-5.2bn guidance will show if the outlook is on track.

Global Market Insights

BAVA.CO Stock Today: February 15 – Travel Health +30%, 2026 Guide Lower

ByDanny Kontos February 16, 2026February 16, 2026

Bavarian Nordic stock is in focus today as Travel Health grew 30% in 2025 while management guided 2026 revenue to DKK 5.0-5.2bn with about a 25% EBITDA margin. Public Preparedness is normalizing as mpox demand eases, with DKK 1.3bn already contracted for 2026. For US investors, the mix shift toward travel vaccine growth could support profitability even as topline steps down. We see near-term attention on order timing, margin discipline, and any updates to 2026 guidance for BAVA.CO.